Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour‐related pain

By  

EUROPEAN JOURNAL OF PAIN (ELECTRONIC), Vol. 20, Iss. 9, 2016-10 ,pp. : 1513-1518

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of chronic moderate-to-severe non-malignant pain with polymer-coated extended-release morphine sulfate capsules

By Nicholson Bruce   Ross Edgar   Weil Arnold   Sasaki John   Sacks Gerald  

Current Medical Research and Opinion, Vol. 22, Iss. 3, 2006-03 ,pp. : 539-550

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain

By Clark A.J.   Ahmedzai S.H.   Allan L.G.   Camacho F.   Horbay G.L.A.   Richarz U.   Simpson K.  

Current Medical Research and Opinion, Vol. 20, Iss. 9, 2004-09 ,pp. : 1419-1428

Informa Healthcare

Access to resources Recommend Favorite

Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?

By Candiotti Keith A.   Gitlin Melvin C.  

Current Medical Research and Opinion, Vol. 26, Iss. 7, 2010-07 ,pp. : 1677-1684

Informa Healthcare

Access to resources Recommend Favorite

Effectiveness and Safety of Tapentadol Prolonged Release (PR) Versus a Combination of Tapentadol PR and Pregabalin for the Management of Severe, Chronic Low Back Pain With a Neuropathic Component: A Randomized, Double‐blind, Phase 3b Study

By  

PAIN PRACTICE, Vol. 15, Iss. 5, 2015-06 ,pp. : 455-470

John Wiley & Sons Inc

Access to resources Recommend Favorite